EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer

BACKGROUND: Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kamel–Reid, S., Chong, G., Ionescu, D.N., Magliocco, A.M., Spatz, A., Tsao, M., Weng, X., Young, S., Zhang, T., Soulieres, D.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2012
Assuntos:
Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3320234/
https://ncbi.nlm.nih.gov/pubmed/22514499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.862
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados